Metabolite Biomarker Detection for Asphyxia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable monitoring of oxygen-induced damages, particularly brain damages, during hyperbaric oxygen therapy, and there is an urgent need for early diagnosis and timely treatment of asphyxia, especially in newborns, as well as effective monitoring of oxygen therapy to prevent adverse neurodevelopmental impairments.
Innovation Solution
A method for in vitro diagnosing asphyxia and estimating duration of hypoxia by detecting specific endogenous compounds in biological samples, using a combination of compound selection, measurement, calibration, and classification algorithms to assess asphyxia status and oxygen therapy effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical signs such as neuromuscular spasms are used to monitor oxygen toxicity during HBO therapy, then the monitoring method is simple, but the reliability and early detection capability are insufficient
Solution Approach 1:
The patent introduces metabolites as intermediary biomarkers that mediate between oxygen therapy and brain damage. These metabolites serve as detectable proxies that reflect oxygen toxicity effects before clinical signs appear, enabling reliable early monitoring without complex equipment.
Solution Approach 2:
The patent replaces mechanical/clinical monitoring methods with biochemical detection methods. Instead of relying on physical signs like neuromuscular spasms, the system uses chemical analysis of metabolites in biological samples to monitor oxygen toxicity, improving reliability while maintaining simplicity.
2Reliability
If hypothermia therapy is delayed, then the neuroprotective potential is reduced, but implementing early therapy requires faster diagnosis capabilities
Solution Approach 1:
The patent enables preliminary diagnosis of asphyxia and hypoxia by detecting specific metabolite patterns in biological samples taken immediately after the suspected event. This allows early identification of patients who need hypothermia therapy before neurological damage occurs, capturing the critical early treatment window.
Solution Approach 2:
The patent establishes feedback loops where metabolite detection provides real-time information about hypoxia status and treatment response. This feedback enables continuous monitoring and timely adjustment of therapy, ensuring optimal timing for neuroprotective interventions.
3Productivity
If excess oxygen is administered for resuscitation, then immediate breathing support is improved, but protein synthesis is inhibited and apoptosis is increased
Solution Approach 1:
The patent uses metabolite detection to monitor oxygen therapy effects in real-time, providing feedback that allows clinicians to adjust oxygen administration. This enables maintenance of beneficial oxygen levels while avoiding excessive oxygen that would inhibit protein synthesis and promote apoptosis.
Solution Approach 2:
The patent monitors changes in metabolite parameters to detect oxygen toxicity early. By tracking metabolic parameter changes, the system enables dynamic adjustment of oxygen therapy parameters, optimizing the balance between resuscitation effectiveness and preventing oxygen-induced cellular damage.
Data Source
AI summary
A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.